Add Yahoo as a preferred source to see more of our stories on Google. (NewsNation) — Some drugmakers are working on a potential breakthrough for people who take weight loss drugs: fewer injections.
Pfizer said its experimental obesity drug, which it acquired through Metsera, drove solid weight loss when taken once a month in a mid-stage trial. The data offer early evidence that the injection can ...
Hosted on MSN
Pfizer’s new weight-loss shot: Can one injection a month change obesity treatment as we know it?
Pharmaceutical giant Pfizer has unveiled encouraging mid-stage trial results for berobenatide, an experimental anti-obesity and diabetes drug designed to be taken just once a month. If approved, it ...
Pfizer has reported promising mid-stage trial results for berobenatide, an experimental weight-loss and diabetes medication that could become the world's first once-a-month GLP-1 injection if approved ...
Pfizer Inc. enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution, despite an aggressive strategic repositioning. The $10 billion Metsera acquisition ...
For millions of people taking weight loss drugs, the next breakthrough may not be more weight loss. It may be fewer injections. Pfizer and Amgen are developing monthly GLP-1 shots — a departure from ...
A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Pfizer made ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results